Based on the IVERIC Bio stock forecast from 8 analysts, the average analyst ISEE stock price target is USD 22.40 over the next 12 months. IVERIC bio Inc’s average analyst rating is Buy. Stock Target Advisor’s own stock analysis of IVERIC Bio stock is Slightly Bearish, which is based on 2 positive signals and 3 negative signals. At the last closing, IVERIC Bio stock price was USD 15.70. IVERIC Bio stock price has changed by +5.71% over the past week, +2.89% over the past month and +72.15% over the last year.
About IVERIC Bio Inc. (ISEE:NSD):
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey.
What we like:
High market capitalization:
ISEE stock is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth:
IVERIC Bio stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What we don’t like:
Overpriced compared to book value:
ISEE stock price is trading high compared to its peers median on a price to book value basis.
IVERIC Bio had negative total cash flow in the most recent four quarters.
Negative free cash flow:
IVERIC Bio had negative total free cash flow in the most recent four quarters.
Stock Target Advisor is not a broker/dealer, investment advisor, or platform for making stock buying or selling decisions. Our goal is to democratize and simplify financial information through automated analysis, aggregation of stock information, and education to help investors with their research. No content on our site, blogs or newsletters constitutes – or should be understood as constituting – a recommendation to enter into any securities transactions or to engage in any of the investment strategies presented in our site content. We also cannot guarantee the accuracy of any information presented on our site and in our analysis.